bupropion and Aging
bupropion has been researched along with Aging in 13 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to assess the effects of the antidepressant bupropion on anxiety and novelty-seeking in adolescent mice of different ages and adults." | 7.79 | Bupropion induced changes in exploratory and anxiety-like behaviour in NMRI male mice depends on the age. ( Carrasco, MC; Redolat, R; Vidal, J, 2013) |
| "Insulin resistance was also assessed at the end." | 6.71 | Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. ( Alvarez, F; Botella-Carretero, JI; Cantarero, M; Escobar-Morreale, HF; García, G; Martín, I; Valero, AM; Varela, C, 2004) |
| " BAG was also not associated with a change in depression severity over time across both arms in the blinded phase or in the subsequent open-label bupropion phase." | 5.51 | Structural MRI-Based Measures of Accelerated Brain Aging do not Moderate the Acute Antidepressant Response in Late-Life Depression. ( Ahmed, R; Bermudez, C; Boyd, BD; Christman, S; Elson, D; Kang, H; Landman, BA; Ryan, C; Szymkowicz, SM; Taylor, WD, 2022) |
| "Bupropion and smoking cessation counseling are underutilized even when provided within the context of a randomized trial." | 5.17 | Factors associated with discontinuation of bupropion and counseling among African American light smokers in a randomized clinical trial. ( Ahluwalia, JS; Benowitz, NL; Buchanan, TS; Cox, LS; Faseru, B; Mayo, MS; Nollen, NL; Tyndale, RF, 2013) |
| "The aim of this study was to assess the effects of the antidepressant bupropion on anxiety and novelty-seeking in adolescent mice of different ages and adults." | 3.79 | Bupropion induced changes in exploratory and anxiety-like behaviour in NMRI male mice depends on the age. ( Carrasco, MC; Redolat, R; Vidal, J, 2013) |
| "Insulin resistance was also assessed at the end." | 2.71 | Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine. ( Alvarez, F; Botella-Carretero, JI; Cantarero, M; Escobar-Morreale, HF; García, G; Martín, I; Valero, AM; Varela, C, 2004) |
| " Understanding the pharmacokinetic (PK) properties and formulations of bupropion can help optimize clinical use." | 2.43 | Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. ( Jefferson, JW; Muir, KT; Pradko, JF, 2005) |
Research
Studies (13)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Ahmed, R | 1 |
| Ryan, C | 1 |
| Christman, S | 1 |
| Elson, D | 1 |
| Bermudez, C | 1 |
| Landman, BA | 1 |
| Szymkowicz, SM | 1 |
| Boyd, BD | 1 |
| Kang, H | 1 |
| Taylor, WD | 1 |
| Carrasco, MC | 2 |
| Vidal, J | 2 |
| Redolat, R | 3 |
| Nollen, NL | 1 |
| Mayo, MS | 1 |
| Ahluwalia, JS | 1 |
| Tyndale, RF | 1 |
| Benowitz, NL | 1 |
| Faseru, B | 1 |
| Buchanan, TS | 1 |
| Cox, LS | 1 |
| Pearce, RE | 1 |
| Gaedigk, R | 1 |
| Twist, GP | 1 |
| Dai, H | 1 |
| Riffel, AK | 1 |
| Leeder, JS | 1 |
| Gaedigk, A | 1 |
| Gómez, C | 1 |
| Carrasco, C | 1 |
| Iñiguez, SD | 1 |
| Warren, BL | 1 |
| Parise, EM | 1 |
| Alcantara, LF | 1 |
| Schuh, B | 1 |
| Maffeo, ML | 1 |
| Manojlovic, Z | 1 |
| Bolaños-Guzmán, CA | 1 |
| Spencer, TJ | 1 |
| Botella-Carretero, JI | 1 |
| Escobar-Morreale, HF | 1 |
| Martín, I | 1 |
| Valero, AM | 1 |
| Alvarez, F | 1 |
| García, G | 1 |
| Varela, C | 1 |
| Cantarero, M | 1 |
| Gómez, MC | 1 |
| Jefferson, JW | 1 |
| Pradko, JF | 1 |
| Muir, KT | 1 |
| Su, SW | 1 |
| Cherng, CF | 1 |
| Lin, YC | 1 |
| Yu, L | 1 |
| Gazzara, RA | 1 |
| Andersen, SL | 1 |
| Marshall, JF | 1 |
| Altar, CA | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Enhancing Tobacco Use Treatment for African American Light Smokers[NCT00666978] | Phase 4 | 540 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Trial Outcomes
Number of Participants With Salivary Cotinine-verified Smoking Abstinence at 6 Months
Salivary cotinine-verified smoking abstinence at 6 months. A cut point of 15 ng/ml was used to differentiate smokers from nonsmokers. (NCT00666978)
Timeframe: 6 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Bupropion Arm | 36 |
| Placebo Arm | 27 |
Number of Participants for Each CYP2B6 Allele
We genotyped CYP2B6 in 268 from the Bupropion arm as this polymorphism is related to bupropion metabolism. (NCT00666978)
Timeframe: Week 3
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| CYP2B6*4 Allele Frequency | CYP2B6*5 Allele Frequency | CYP2B6*6 Allele Frequency | CYP2B6*9 Allele Frequency | CYP2B6*16 Allele Frequency | CYP2B6*18 Allele Frequency | CYP2B6*22 Allele Frequency | |
| Bupropion Arm | 2 | 6 | 95 | 0 | 0 | 17 | 6 |
Number of Slow and Fast Metabolizers by Genotype
"Analyzed CYP2A6 by genotype. The variants present in people in the slow genotype group include *17, *20, *23,*27, *35, *9, *2, *25, *26, and *4. The fast metabolizers have none of the variant alleles tested.~Slow metabolizers have any reduction or loss of function variant. Fast metabolizers are *1/*1 genotype by exclusion." (NCT00666978)
Timeframe: Week 0
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Slow Metabolizers by Genotype | Fast Metabolizers by Genotype | |
| All Study Participants | 265 | 269 |
Number of Slow and Fast Metabolizers by Metabolite Ratio
"Analyzed CYP2A6 by activity, called the nicotine metabolite ratio using a split between slow and fast metabolism at 0.31.~The variants present in people in the slow genotype group include *17, *20, *23,*27, *35, *9, *2, *25, *26, and *4. The fast metabolizers have none of the variant alleles tested.~Blood samples were collected for 3HC/COT ratio at Week 0." (NCT00666978)
Timeframe: Weeks 0
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Fast Metabolizers by Nicotine Metabolite Ratio | Slow Metabolizers by Nicotine Metabolite Ratio | |
| All Study Participants | 236 | 214 |
Reviews
2 reviews available for bupropion and Aging
| Article | Year |
|---|---|
ADHD treatment across the life cycle.
Topics: Adolescent; Adult; Aging; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic | 2004 |
Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Area Under Curve; Aryl Hydrocarbon Hydroxy | 2005 |
Trials
3 trials available for bupropion and Aging
| Article | Year |
|---|---|
Structural MRI-Based Measures of Accelerated Brain Aging do not Moderate the Acute Antidepressant Response in Late-Life Depression.
Topics: Aging; Antidepressive Agents; Brain; Bupropion; Depression; Humans; Magnetic Resonance Imaging | 2022 |
Factors associated with discontinuation of bupropion and counseling among African American light smokers in a randomized clinical trial.
Topics: Aging; Black or African American; Bupropion; Counseling; Delayed-Action Preparations; Female; Humans | 2013 |
Weight gain and cardiovascular risk factors during smoking cessation with bupropion or nicotine.
Topics: Administration, Cutaneous; Adult; Aging; Blood Pressure; Bupropion; Cardiovascular Diseases; Diastol | 2004 |
Other Studies
8 other studies available for bupropion and Aging
| Article | Year |
|---|---|
Bupropion induced changes in exploratory and anxiety-like behaviour in NMRI male mice depends on the age.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Dose-Response Relation | 2013 |
Developmental Expression of CYP2B6: A Comprehensive Analysis of mRNA Expression, Protein Content and Bupropion Hydroxylase Activity and the Impact of Genetic Variation.
Topics: Adolescent; Adult; Age Factors; Aged; Aging; Biotransformation; Bupropion; Child; Child, Preschool; | 2016 |
Adolescent and adult mice display differential sensitivity to the effects of bupropion on the acquisition of a water maze task.
Topics: Age Factors; Aging; Animals; Antidepressive Agents, Second-Generation; Bupropion; Dose-Response Rela | 2017 |
Nicotine exposure during adolescence induces a depression-like state in adulthood.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cholinergic Agents; De | 2009 |
Effects of acute bupropion administration on locomotor activity in adolescent and adult mice.
Topics: Aging; Animals; Bupropion; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Male; Mice; | 2005 |
Prenatal exposure of bupropion may enhance agitation, anxiety responses, and sensitivity to cocaine effects in adult mice.
Topics: Aging; Animals; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Cocaine; Dose-Response | 2007 |
The effects of bupropion in vivo in the neostriatum of 5-day-old and adult rats.
Topics: Aging; Animals; Animals, Newborn; Bupropion; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Rel | 1997 |
Striatal dopamine uptake and swim performance of the aged rat.
Topics: Aging; Animals; Bupropion; Corpus Striatum; Desipramine; Dopamine; Dopamine Antagonists; Male; Motor | 1986 |